The major role of androgens in prostate cancer and the need for more efficient blockade

Expert Review of Endocrinology and Metabolism

Volumn 6, Issue 3, 2011, Pages 313-316

  Labrie, Fernand ^a,b  

^a UNIVERSITÉ LAVAL   (Canada)

^b AL IMAM MOHAMMAD IBN SAUD ISLAMIC UNIVERSITY IMSIU   (Saudi Arabia)

Author keywords

androgens; antiandrogens; enzyme inhibitors; GnRH agonists; intracrinology; prostate cancer

Indexed keywords

ABIRATERONE; ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; ANTIANDROGEN; BICALUTAMIDE; ESTROGEN; FLUTAMIDE; GONADORELIN AGONIST; NILUTAMIDE; PRASTERONE; PROSTATE SPECIFIC ANTIGEN;

ANDROGEN SYNTHESIS; CANCER MORTALITY; CANCER SURVIVAL; CASTRATION; DRUG MEGADOSE; ENZYME INHIBITION; HUMAN; NONHUMAN; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RECEPTOR BLOCKING; REVIEW; TESTIS; TESTOSTERONE RELEASE;

EID: 79956100433     PISSN: 17446651     EISSN: 17448417     Source Type: Journal    
DOI: 10.1586/eem.11.5     Document Type: Review

References (40)

1. Lichtenberg F. Measuring the health impacts of medical innovation and expenditure. In: Health Services Research Seminal Series 2002-2003. University of Minnesota, Minneapolis, MN, USA (2002).
2. Labrie F, Bélanger A, Cusan L, et al. Antifertility effects of LHRH agonists in the male. J. Androl. 1, 209-228 (1980).
3. Labrie F, Dupont A, Bélanger A. Complete androgen blockade for the treatment of prostate cancer. In: Important Advances in Oncology. de Vita VT, Hellman S, Rosenberg SA (Eds). JB Lippincott, PA, USA, 193-217 (1985).
4. Labrie F. Multiple intracrine hormonal targets in the prostate: opportunities and challenges. BJU Int. 100(Suppl. 2), 48-51 (2007). (Pubitemid 46985614)
5. Arnst C. Developments to watch. Why did prostate cancer death rates fall? Business Week 92, 3853 (2003).
6. Peto R, Dalesio O. Breast and prostate cancer: 10-year survival gains in the hormonal adjuvant treatment trials. Eur. J. Cancer Suppl. 1, S101(Abstract 32B) (2003).
7. Labrie F, Cusan L, Gomez JL, et al. Comparable amounts of sex steroids are made outside the gonads in men and women: strong lesson for hormone therapy of prostate and breast cancer. J. Steroid Biochem. Mol. Biol. 113, 52-56 (2009).
8. Labrie F, Candas B, Gomez JL, Cusan L. Can combined androgen blockade provide long-term control or possible cure of localized prostate cancer? Urology 60(1), 115-119 (2002). (Pubitemid 34722958)
9. Akaza H, Hinotsu S, Usami M, et al. The case for androgen deprivation as primary therapy for early stage disease: results from J-CaP and CaPSURE. J. Urol. 176(6 Pt 2), S47-S49 (2006). (Pubitemid 44648136)
10. Ueno S, Namiki M, Fukagai T, Ehara H, Usami M, Akaza H. Efficacy of primary hormonal therapy for patients with localized and locally advanced prostate cancer: a retrospective multicenter study. Int. J. Urol. 13(12), 1494-1500 (2006). (Pubitemid 44786336)
11. Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N. Engl. J. Med. 321(7), 419-424 (1989). (Pubitemid 19211484)
12. Denis LJ, Keuppens F, Smith PH, et al. Maximal androgen blockade: final analysis of EORTC Phase III trial 30853. Eur. Urol. 33, 144-151 (1998). (Pubitemid 28073756)
13. Bennett CL, Tosteson TD, Schmitt B, Weinberg PD, Ernstoff MS, Ross SD. Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer: a meta-analysis of nine published randomized controlled trials and patients using flutamide. Prostate Cancer Prostatic Dis. 2, 4-8 (1999). (Pubitemid 29096321)
14. Prostate Cancer Triallists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 355, 1491-1498 (2000).
15. Labrie F, Veilleux R. A wide range of sensitivities to androgens develops in cloned Shionogi mouse mammary tumor cells. Prostate 8, 293-300 (1986). (Pubitemid 16109155)
16. Labrie F, Dupont A, Giguère M, et al. Benefits of combination therapy with Flutamide in patients relapsing after castration. Br. J. Urol. 61, 341-346 (1988).
17. Dupont A, Gomez JL, Cusan L, Koutsilieris M, Labrie F. Response to Flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J. Urol. 150, 908-913 (1993). (Pubitemid 23241297)
18. Collinson MP, Daniel F, Tyrrell CJ, Teasdale C. Response of carcinoma of the prostate to withdrawal of flutamide. Br. J. Urol. 72(5 Pt 1), 662-663 (1993). (Pubitemid 23357202)
19. Kelly WK, Scher HI. Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J. Urol. 149, 607-609 (1993). (Pubitemid 23094069)
20. Labrie F, Veilleux R, Fournier A. Low androgen levels induce the development of androgen-hypersensitive cells clones in Shionogi mouse mammary carcinoma cells in culture. J. Natl Cancer Inst. 80, 1138-1147 (1988).
21. Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat. Med. 10(1), 33-39 (2004). (Pubitemid 38524696)
22. Mulders PF, Schalken JA. Measuring therapeutic efficacy in the changing paradigm of castrate-resistant prostate cancer. Prostate Cancer Prostatic Dis. 12(3), 241-246 (2009).
23. McPhaul MJ. Mechanisms of prostate cancer progression to androgen independence. Best Pract. Res. Clin. Endocrinol. Metab. 22(2), 373-388 (2008). (Pubitemid 351611961)
24. Labrie C, Bélanger A, Labrie F. Androgenic activity of dehydroepiandrosterone and androstenedione in the rat ventral prostate. Endocrinology 123, 1412-1417 (1988).
25. El-Alfy M, Luu-The V, Huang XF, Berger L, Labrie F, Pelletier G. Localization of type 5 17b-hydroxysteroid dehydrogenase, 3b-hydroxysteroid dehydrogenase and androgen receptor in the human prostate by in situ hybridization and immunocytochemistry. Endocrinology 140(3), 1481-1491 (1999). (Pubitemid 29104255)
26. Nakamura Y, Suzuki T, Nakabayashi M, et al. In situ androgen producing enzymes in human prostate cancer. Endocr. Relat. Cancer 12(1), 101-107 (2005). (Pubitemid 40477091)
27. Rosner JM, Macome JC, Cardinali DP. In vitro biosynthesis of sterols and steroids by rat submaxillary glands. Endocrinology 85, 1000-1003 (1969).
28. Voutilainen R, Miller WL. Developmental expression of genes for the stereoidogenic enzymes P450scc (20,22-desmolase), P450c17 (17 a-hydroxylase/17,20-lyase), and P450c21 (21-hydroxylase) in the human fetus. J. Clin. Endocrinol. Metab. 63(5), 1145-1150 (1986). (Pubitemid 17173052)
29. Akaza H, Yamaguchi A, Matsuda T, et al. Superior anti-tumor efficacy of bicalutamide 80 mg in combination with a luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist monotherapy as first-line treatment for advanced prostate cancer: interim results of a randomized study in Japanese patients. Jpn J. Clin. Oncol. 34(1), 20-28 (2004). (Pubitemid 43115330)
30. Dupont A, Labrie F, Giguere M, et al. Combination therapy with flutamide and [D-Trp6]LHRH ethylamide for stage C prostatic carcinoma. Eur. J. Cancer Clin. Oncol. 24(4), 659-666 (1988). (Pubitemid 18095570)
31. Dupont A, Cusan L, Gomez JL, et al. Combination therapy with flutamide and the LHRH agonist [D-Trp6-des-Gly-NH2] LHRH ethylamide in stage C prostatic carcinoma. Br. J. Urol. 72, 629-634 (1993). (Pubitemid 23357191)
32. Labrie F, Simard J, Singh SM, Candas B. Estimated potency of Casodex: a problematic design. Urology 50, 309-313 (1997).
33. Debes JD, Tindall DJ. Mechanisms of androgen-refractory prostate cancer. N. Engl. J. Med. 351(15), 1488-1490 (2004). (Pubitemid 39315314)
34. Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324(5928), 787-790 (2009).
35. Reid AH, Attard G, Danila DC, et al. Significant and sustained antitumor activity in post-docetaxel, castrationresistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J. Clin. Oncol. 28(9), 1489-1495 (2010).
36. Attard G. Selective inhibition of CYP17 with abiraterone acetate is highly active incastration-resistant prostate cancer. Presented at: 14th International Congress on Hormonal Steroids and Hormones & Cancer. Edinburgh, UK, September 21-24 2010.
37. Labrie F. Hormonal therapy of prostate cancer. In: Neuroendocrinology, The Normal Neuroendocrine System. Progress in Brain Research. Martini L, Chrousos GP, Labrie F, Pacak K, Pfaff DW (Eds). Elsevier, Amsterdam, The Netherlands, 321-341 (2010).
38. Labrie F. Intracrinology. Mol. Cell. Endocrinol. 78, C113-C118 (1991).
39. Labrie F, Candas B, Cusan L, et al. Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen. Urology 47, 212-217 (1996). (Pubitemid 26075276)
40. SCRIP Intelligence. J&J to file abiraterone early after strong Phase III results www.scripintelligence.com/home/JandJ-to-file-abiraterone-early- after-strong-Phase-III-results-304131